Brad Patt 0:03
I'm Brad Patt. I'm co founder, chairman and CEO of Tetrous. Tetrous is transforming sports medicine, and the healing paradigm in sports medicine, by stimulating and for the first time achieving the RE formation of, by the way, this the clicker, thanks, the reformation of the tissue that connects the bone to the tendon. So, our technology addresses multiple, multiple aspects of Sports Medicine and multiple anatomies. But the first foray that we have is in the rotator cuff market, this market on its own is over a billion dollar market for us, because it involves 500,000 surgeries a year. And according to our sir, our first surgeons, our products really have application, every single one of these surgeries. Why is that true? That's true, because we're addressing one of the key failure modes in those surgeries that leads to revision. So there are a ton of products out there sutures, suture anchors that are used to achieve the mechanical fixation when you pull the tendon back over the bone. And recently, there have been some new products added overlay patches that go over the tendon to heal the tendon. But these have absolutely nothing to help heal that critical junction between the tendon and the bone. That's what we address with our technology. And, and the way that we do that is we completely flip the script by going in between the bone and the tendon. So for the first time, we have a material that's given us a biological reformation of the tendon, we implant into the bone that starts in the endochondral ossification cascade that flows up through the bone into the emphasis the region between the bone and the tendon and into the tendon, providing connective tissue between the bone and the tendon. Without that all you get is scar tissue. For the first time, we're getting real healing of that emphasis. With us, it's all about the emphasis and how we heal there. Tetris evolved from a company called carousel carousel was a spine Allah graft company. And before we had before we were acquired by Israel biologics in April of 22, we spun out the sports medicine uses of the technology. Because of that, we have experienced now with the core technology in the Tetris products in over 150,000 surgeries over a five year period. So we know that this technology is good and it works. In addition, we've been able to leverage our manufacturing partners that we hadn't Thermacell to manufacture for us, both in Australia and the United States. And that has allowed us to really speed up our entry into the market. And today we provide a product mix, you can see the different products that we have, we provide a product mix that literally covers every surgical procedure for rotator cuff in the US. In the next slide will present a video that shows the infix RC product that's the product that's used with a suture anchor, and it will explain how the procedure is done and how that biological healing process starts.
Video Playing 3:38
failure rates of rotator cuff surgical repairs have remained stubbornly high. Due to insufficient healing of native tendon tissue at the emphasis Tetra sink has developed and fix our C, the first D mineralized bone fiber technology to directly address synthesis repair in rotator cuff surgery. We focus on enhanced healing at the tendon to bone interface, also providing improved suture anchor fixation and fix our C is designed to easily integrate into current surgical techniques and to simplify the delivery of the fiber implant into the synthesis to augment the repair. Preparation for rotator cuff repair proceeds as usual, and all is used to make the suture anchor insertion site. The infix RC is placed on the introducer and inserted into the hole then the introducer is removed. A TAP is used to receive the suture anchor and the suture anchor is inserted. Additional implants and suture anchors are inserted as needed, and the repair is completed in the usual manner. Once implanted healing proceeds with cells being whipped up into the D mineralized bone fiber implant. Them remodeling occurs over Time to form new tissue with the emphasis and to reinforce the bone around the suture anchor. in preclinical studies, reformation of the emphasis is seen at 12 weeks, and Vicks RC, a novel approach to enthesis Failure syndrome from Tetra sake.
Brad Patt 5:19
We've done a broad series of experiments and preclinical studies using sheep and rabbits, essentially to look at the whole progression. So initially at time zero, we show on the left hand panel, that compared to a control with the unfix RC, we get better fixation in the bone at t equals zero. And then over time, that demineralized bone matrix turns into new woven bone, securing the long term healing and fixation in bone. Above the bone, what we see is beautiful new emphasis biology formed where you can see the sharpies fibers, these are the connective tissue that now extends from the bone through the emphasis and into the tendon providing the strength of that new structure. And we see that then in this animal study, where compared to the control, you can see the dark blue bars, that we have improved strength of the attachment of the bone to the tendon. We've just started now we did our first case is roughly the first of July of last year, and we're starting to get back the six month MRIs. And they really look look stunning. We're seeing complete reformation of the of the synthesis and proper healing at the synthesis. we're even seeing it extended to the tendon and thickening of the tendon at that at that point. And interestingly, we're seeing we're seeing no evidence of the type of edema or bone cysts that you would normally find in bone, which is you know, evidence of the way that the unfix RC is working in bone. We have we have an exclusive license to the dbf technology, the core technology behind the products from the carousel sale, we also have our own patents on the product itself, from a regulatory point of view in the US were considered 361 exempt minimally manipulated tissue were approved in Australia as well. And we have a very clear understanding of the reimbursement with reimbursement by commercial insurance and workers comp. Commercially since we launched on the first of July now in two countries, we're actually close to 200 cases today with around 400 implants. It was a controlled launch with a half a dozen surgeons and we're now expanding more broadly, both in the US and Australia. It's really, it's really all about the emphasis. So wherever you have tendon joint bone, we're going to attack those large additional high value procedures. We have an experienced team, we have most of the team intact from carousel and the sale to so biologics, we've added to the team as well. We between us we have many trade sales in this in the orthopedic space are adjacent spaces recently, and really who's who advisory board including that Verma who's he was the head team physician for the Chicago White Sox. In terms of capitalization, we've been extremely efficient, we've got to where we're at today, with three and a quarter million dollars invested into the company that took us through the successful launch of the product in the first 200 cases. We've now just initiated January 1 a $5 million round for the company and have about two and a half million of that committed already in the bank. And we're extremely excited because this is a space where there are very high value deals being done. And deals that are being done with companies that are revenues in the single digit millions with literally 200x revenue type of exit. So very exciting for us to be in the space with a very novel product. In summary, high value, high value part of the market. We address this unsolved issue in emphasis failure syndrome. Our product has a proven history with five years and 150,000 implants in an adjacent space. We have strong preclinical data supporting the the the the product as well as early clinical data were fully commercialized in the US and Australia with partners that have experienced in this product for five years. There are no regulatory hurdles for our future products addressing other anatomies clear reimbursement landscape and and clinical experience with a experienced team anyone is interested please look myself up or or John budget outski who's here with me my partner would be love to talk with you. Thank you
© 2024 Life Science Intelligence, Inc., All Rights Reserved.
